Upon respiratory syncytial virus (RSV) challenge, mice previously immunized intramuscularly with inactivated whole virus express a Th2-like pattern of cytokine mRNA, while mice immunized with live virus intranasally express a Thllike pattern. In this study, we evaluated the effects of anti-IL-4 treatment on the induction of immune responses after immunization. Mice treated with anti-IL-4 at the time of immunization with inactivated RSV had reduced clinical illness after live virus challenge, as measured by weight loss, illness score, and virus replication. This was associated with an augmented CD8+ cytotoxic T lymphocyte (CTL) activity, increased expression of IFN-y mRNA relative to IL-4 mRNA, and a higher titer of RSV-specific IgG2. in the anti-IL-4 treated mice before challenge. Anti-IL-4 administration at the time of challenge had no effects on illness, immunoglobulin isotype, or cytokine patterns. These results suggest that inhibition of IL-4 action at immunization can shift the selective activation of lymphocytes to a more Thl-like response. This cytokine milieu is associated with augmented CTL activity, which may be the factor responsible for rapid viral clearance and reduced illness at the time of remote RSV challenge. (J. Clin. Invest. 1994Invest. . 94:1953Invest. -1958
Introduction
Respiratory syncytial virus (RSV)' is an important cause of respiratory illness in children and adults. A formalin-inactivated, alum-precipitated whole RSV vaccine preparation given intramuscularly did not protect children from infection. Moreover, the illness accompanying subsequent infection was unusually severe, with some deaths and an increased rate of hospitalization (1) (2) (3) (4) . In contrast, clinical trials of live attenuated RSV vaccine products, such as temperature-sensitive mutants (5, 6) or cold-adapted strains (7, 8) , did not result in enhanced illness, but had limited success because of reversion to wild type virulence or lack of immunogenicity.
Recently, murine T helper cells have been subdivided into two distinct subsets on the basis of their patterns of cytokine secretion: Thl cells, expressing interleukin 2 (IL-2), interferony (IFN-y), and tumor necrosis factor-,8 (TNF-/3), mediate delayed-type hypersensitivity, while Th2 cells, expressing IL-4, IL-5, IL-6, and IL-1O, provide efficient help for antibody-producing lymphocytes (9, 10) . Different subsets of T-helper cells have been reported to determine disease expression through the release of different cytokines (11) . In general, immunization that leads to a dominant IL-4 response from T cells is associated with disease progression, while immunization which leads to dominant IFN-y production is protective (10) . This pattern of IFN-y-associated protection and IL-4-associated disease progression has been noted in Leishmania major ( 12) , Toxoplasma gondii (13) , Schistosoma mansoni (14) , Candida albicans (15) , and the murine acquired immunodeficiency syndrome (16) in mouse models, and leprosy (17) , measles (18) , and AIDS (19) in humans.
It has been shown previously that CD4+ T lymphocyte depletion before rechallenge of mice with RSV prevents the development of lymphocytic aggregates and pathology in lungs (20, 21) . Recent evidence suggests that the CD4+ T lymphocytes determine the pathological events through their patterns of cytokine secretion. It has been reported that T cell lines with distinct patterns of cytokine expression can be derived from mice immunized with recombinant vaccinia expressing individual RSV proteins (22) . We (23) . These findings have suggested a potential mechanism for the pathogenesis of RSV vaccine-enhanced illness: RSV immunization can selectively activate subpopulations of lymphocytes which, upon rechallenge, result in different levels of illness expression based on cytokine secretion patterns.
Others have shown that blocking Th2 cytokine expression, either by administering an IL-4 neutralizing antibody (24, 25) or disrupting the IL-4 gene (26, 16) , can result in diminished IL-4 production and improved disease outcome in models of other infectious diseases. In contrast, treatment with anti-IFNy can result in a more Th2-like immune response causing increased mortality (15) . We report here that a brief treatment of mice with anti-IL-4 at the time of whole inactivated RSV immunization results in diminished illness and more rapid viral clearance after subsequent live RSV challenge. This was associ-ated with an augmented CD8+ cytotoxic T lymphocyte (CTL) activity in lungs and a shift from a Th2-like to a more ThI-like pattern of cytokine expression.
Methods
Mice, virus, monoclonal antibody, and illness assessment. Pathogenfree female BALB/c mice, 8-10 mo old, were purchased from Charles River Laboratories (Raleigh, NC) and cared for according to the "Guide for the Care and Use of Laboratory Animals" as previously described (27) . Preparation of the formalin-inactivated, alum-precipitated RSV (23) and preparation of stock of the A2 strain of RSV (28) plates were washed and substrate was added for 30 min at room temperature and OD45 was determined (27) . A serum dilution was considered positive if the mean optical density of two BCH4 cell wells was greater than twice that of BC-coated wells and greater than 0.1. mRNA extraction, Northern blotting, and cytokine detection. Lungs were removed promptly and quick-frozen in liquid nitrogen before storage at -70°C. Tissues were then homogenized in 4M GITC working solution (30) by a Tissumizer (Tekmar Co., Cincinnati, OH). The total RNA was extracted and polyA RNA isolated on oligo (dT) cellulose (GIBCO BRL, Gaithersburg, MD) as previously described (30) . The polyA mRNA was electrophoretically separated through a 1.5% agarose denaturing gel and transferred to Zetabind membrane (Cuno Inc., Meriden, CT). Membranes were treated with 160 mJ of UV light (Stratlinker 1600, Stratagene, La Jolla, CA) and baked at 80-100°C for 2 h. Hybridization with 32p oligonucleotide probes for IL-4, IFN-y, and a-tubulin was performed as previously described (23) . After washing, membranes were exposed to Kodak X-omat film at -70TC. Laser (Fig. 1) (Fig. 3) . In addition, the weight loss (P = 0.01) and illness scores (P < 0.01 ) at day 8 were significantly reduced by anti-IL-4 treatment given at the time of immunization (Fig. 4) , and viral replication was also significantly reduced in lungs 4 d after challenge (Fig.  4 , P = 0.03). However, treatment of mice with anti-WL-4 at the time of challenge had no effect on cytokine mRNA patterns (Fig. 3) or illness (Fig. 4) . to a more Thl-like response while interference at the time of challenge has no effect. RSV-specific cytotoxicity activity. 5tCr release assays were performed to define factors associated with diminished illness. A direct CTL assay using lung lymphocytes was employed that does not include in vitro stimulation (32) . Using this method, CTL activity was detected on day 7 after primary live RSV challenge (Fig. 6) . In mice treated with anti-IL-4 at the time of immunization, CTL activity was increased above that in immunized mice that did not receive anti-IL-4. This result was repeated in two consecutive experiments. The activity was RSVspecific and lysed only syngeneic RSV-infected target cells. The phenotype of lymphocytes responsible for the cytolytic activity was then determined in another independent experiment by an immunomagnetic method to deplete CD4+, CD8+, or both in vitro before incubating effectors with targets. FACS analysis showed that 85-89% of CD4+ and 82-86% of CD3+ cells were effectively depleted by this method (data not shown). CD8+ depletion abolished CTL activity, while CD4+ depletion did not affect CTL activity (data not shown). The FACS data of the total lung lymphocyte population also showed that the proportion of CD8+ lymphocytes was greater in the anti-IL-4 treated group than that in the PBS-treated group (10.6% compared to 3.4%, respectively). These data suggest that anti-IL-4 treatment at the time of immunization resulted in augmented CD8+ CTL activity following subsequent live RSV challenge.
Discussion
We report here that upon live RSV challenge, mice treated with anti-IL-4 neutralizing monoclonal antibody at the time of formalin-inactivated whole RSV immunization showed diminished illness and reduced RSV replication, associated with a shift from a Th2-like to a Thl-like pattern of cytokine expression. The anti-IL-4 treatment also resulted in an augmented RSV-specific CD8+ CTL activity in lung lymphocytes. These results suggest that interference with IL-4 activity at the time of immunization can alter the cytokine milieu at the time of subsequent RSV challenge, resulting in modulation of effector functions and improvement in illness outcome.
The improved illness outcome and reduced RSV replication in lungs after challenge when anti-IL-4 was administered at the time of immunization was associated with an increased expression of IFN-y and a reduced expression of IL-4. While the shift in cytokine mRNA expression was subtle, the increase in RSV-specific IgG2a supports the conclusion that a shift from a dominant Th2-like pattern to a more ThI-like response indeed occurred. We believe a major advantage in measuring cytokine mRNA expression by direct Northern blotting is the increased confidence that subtle changes are real, without the possible distortion of in vitro stimulation.
The treatment with anti-IL-4 was only effective when given at the time of initial RSV antigen presentation. Thus, the nature of the primary immune response to RSV antigens can determine the composition of the response to subsequent challenge. As in other models of infectious pathogens, a more ThI-like pattern of cytokine expression was associated with reduced RSV-induced illness ( 13, 15, 16, 24 Ultimately, the goal of any vaccine is to prevent illness associated with subsequent exposure to the pathogen. Therefore, it is not only important to define the cells producing the cytokine milieu, but to define the effector mechanisms that respond to the vaccine-induced conditions. It is the effector mechanisms that more directly translate into protection from or enhancement of disease. Th2-mediated responses may be detrimental to the host, initiating mechanisms such as mast cell activation and the release of histamine and other soluble factors that promote inflammation and altered smooth muscle tone (34 (20, (31) (32) (36) (37) (38) . Passive transfer experiments utilizing CD8+ RSV-specific T cells have been shown to effectively clear RSV (39) . Transfer of higher doses of RSV-specific CTL in mice has caused a hemorrhagic pneumonitis in some studies (40) , but not others (41) . Recently, it has been shown that the specificity of the CTL effectors and the T cell environment in which they are present can affect the type of lung pathology caused by RSV (42) . We have shown that in vivo induction of RSV-specific CD8+ CTL is associated with rapid viral clearance and reduced illness. We suspect these CD8+ CTL were part of the primary response to live RSV challenge and were not memory CTL induced directly by vaccine. In these experiments the CTL activity was only measured at one time point. Therefore, it is possible that peak CTL activity after challenge was not higher, but rather developed more rapidly in the vaccine-induced cytokine milieu produced by anti-IL-4 treatment.
Our data indicate that interfering with IL-4 activity at the time of immunization can affect the composition of the immune response and reduce illness after subsequent RSV challenge. These findings may be relevant to understanding how a formalininactivated RSV vaccine resulted in enhanced illness in children subsequently infected with RSV (1) (2) (3) (4) . Learning how to modulate the immune response to viral pathogens by selectively activating T cell populations at the time of immunization has the potential to increase vaccine efficacy and improve vaccine safety.
